Hepatic Lipoprotein Export and Remission of Human Type 2 Diabetes after Weight Loss

Cell Metab. 2020 Feb 4;31(2):233-249.e4. doi: 10.1016/j.cmet.2019.11.018. Epub 2019 Dec 19.

Abstract

The role of hepatic lipoprotein metabolism in diet-induced remission of type 2 diabetes is currently unclear. Here, we determined the contributions of hepatic VLDL1-triglyceride production rate and VLDL1-palmitic acid content to changes in intra-pancreatic fat and return of first phase insulin response in a subgroup of the Diabetes Remission Clinical Trial. Liver fat, VLDL1-triglyceride production, and intra-pancreatic fat decreased after weight loss and remained normalized after 24 months of remission. First-phase insulin response remained increased only in those maintaining diabetes remission. Compared with those in remission at 24 months, individuals who relapsed after initial remission had a greater rise in the content of VLDL1-triglyceride and VLDL1-palmitic acid, re-accumulated intra-pancreatic fat, and lost first-phase response by 24 months. Thus, we observed temporal relationships between VLDL1-triglyceride production, hepatic palmitic acid flux, intra-pancreatic fat, and β-cell function. Weight-related disordered fat metabolism appears to drive development and reversal of type 2 diabetes.

Keywords: VLDL1-triglycerides; diabetes remission; human; intra-pancreatic fat; liver fat; palmitic acid; pathophysiology; twin cycle hypothesis; type 2 diabetes; β-cell function.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Diabetes Mellitus, Type 2 / metabolism*
  • Female
  • Humans
  • Insulin-Secreting Cells* / metabolism
  • Insulin-Secreting Cells* / pathology
  • Lipid Metabolism
  • Lipoproteins, VLDL / metabolism*
  • Liver / metabolism
  • Male
  • Middle Aged
  • Palmitic Acid / metabolism*
  • Remission Induction
  • Triglycerides / metabolism*
  • Weight Loss*

Substances

  • Lipoproteins, VLDL
  • Triglycerides
  • Palmitic Acid